Response to the report, "A re-assessment of treatment with a tyrosine kinase inhibitor (imatinib) on tissue sparing and functional recovery after spinal cord injury" by Sharp et al

Exp Neurol. 2014 Jul:257:182-5. doi: 10.1016/j.expneurol.2014.04.025. Epub 2014 May 11.

Authors

Mathew B Abrams¹, Ingrid Nilsson², Jacob Kjell¹, Sebastian Lewandowski², Simone Codeluppi², Ulf Eriksson², Lars Olson³

Affiliations

¹ Department of Neuroscience, Karolinska Institutet, 171 77 Stockholm, Sweden.
² Department of Medical Biochemisty and Biophysics, Karolinska Institutet, 171 77 Stockholm, Sweden.
³ Department of Neuroscience, Karolinska Institutet, 171 77 Stockholm, Sweden. Electronic address: [email protected].

PMID: 24825370
DOI: 10.1016/j.expneurol.2014.04.025

No abstract available

Publication types

Comment

MeSH terms

Animals
Benzamides / pharmacology*
Female
Nerve Regeneration / drug effects*
Piperazines / pharmacology*
Protein Kinase Inhibitors / pharmacology*
Pyrimidines / pharmacology*
Recovery of Function / drug effects*
Spinal Cord Injuries / drug therapy*
Urinary Bladder / drug effects*

Substances

Benzamides
Piperazines
Protein Kinase Inhibitors
Pyrimidines